17:51 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Split intein-based gene therapies for two types of congenital blindness

DISEASE CATEGORY: Ophthalmic disease INDICATION: Blindness Mouse studies suggest gene therapies delivering ABCA4 or CEP290 as split inteins could help treat Stargardt disease or Leber congenital amaurosis type 10 (LCA10), respectively. The therapies consist of...
19:42 , May 6, 2019 |  BC Extra  |  Financial News

May 6 Financial Quick Takes: Athenex, Spiral

Athenex raises $100M to advance Oraxol  Looking to fund commercialization activities for Oraxol and advance its oncology pipeline and actinic keratosis therapy, Athenex Inc. (NASDAQ:ATNX) raised $100 million in a private placement through the sale...
20:50 , Feb 8, 2019 |  BC Week In Review  |  Company News

Sanofi seeking partner to develop Oxford BioMedica's ophthalmology gene therapies

Oxford BioMedica plc (LSE:OXB) said Sanofi (Euronext:SAN; NASDAQ:SNY) will seek a partner to continue further development of two ophthalmology gene therapy programs that the pharma gained under a 2009 deal with Oxford BioMedica. The products...
16:04 , Jul 11, 2018 |  BC Innovations  |  Translation in Brief

Poisoning the stromal chalice

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells. Tumor-associated stroma,...
15:27 , Jun 8, 2018 |  BC Week In Review  |  Company News

Opthotech gains gene therapy for ophran vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and the University of Pennsylvania. The deal gives the biotech an adeno-associated...
20:58 , Jun 7, 2018 |  BC Extra  |  Company News

Ophthotech gains gene therapy for orphan vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) gained $0.29 (10%) to $3.09 on Thursday on news that it acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing...
16:23 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb ACTION 2 trial in the indication. Biogen markets natalizumab, a...
20:34 , Feb 7, 2018 |  BC Extra  |  Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb ACTION 2 trial in the indication. Biogen markets natalizumab, a...